According to Stratistics MRC, the stem cell therapy market is expected to grow at a CAGR of 37.6% during the forecast period 2015 to 2022. Rising awareness about stem cell therapies is the key factor driving the market growth. Furthermore, rising prevalence of chronic diseases, increasing approvals of clinical trials for stem cells therapy, increasing funds from government and private organizations, technological advancements and rising focus towards human embryonic stem cells are some of the drivers fuelling the market growth. However, complications in preservation of stem cells and lack of required infrastructures are the restraints hampering the market growth. Evolution of new therapies and low regulatory frameworks in emerging regions are expected to provide opportunities for market growth over the forecast period.
Browse full report with TOC@ https://marketreportscenter.com/reports/328701/stem-cell-therapy-global-market-outlook-2015-2022
North America is expected to account for the largest share of the global market over the forecast period due to advancements in stem cell therapy and continuous R & D activities on stem cells. Whereas, Asia Pacific is likely to witness highest growth on account of favourable government policies, increasing adoption of stem cell therapy and rising population in China and India.
Some of the key players in stem cell therapy market include Aastrom Biosciences Inc., Cellular Dynamics International Inc., ReNeuron Group plc, Roslin Cells limited, Advanced Cell Technologies Inc., Cytori Therapeutics Inc., Celgene Corporation, Gamida Cell Ltd., International Stem Cell Corp., Mesoblast Ltd., Pluristem Therapeutics Inc., Fibrocell Science Inc., Stemcells Inc., Regeneus Ltd and Athersys Inc.